ZyVersa Therapeutics went public via a SPAC merger with Larkspur Health Acquisition in a $109m deal.

ZyVersa Therapeutics, a company committed to improving patients' health outcomes and quality of life, went public via a SPAC merger with Larkspur Health Acquisition in a $109m deal. "We are delighted to partner with Larkspur in this business combination. Their management and board have vast experience as investors and operating executives in the biopharmaceutical industry. This merger and entry into the public markets will enable us to escalate development of our pipeline drug candidates for targeted patients with renal and inflammatory diseases who have the need for disease-modifying drugs that are well tolerated and safe. We believe our drug candidates in development for these patients have potential to meet these needs and help drive improved health outcomes," Stephen C. Glover, ZyVersa Co-Founder, CEO and Chairman.